

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Joseph M. PENNINGER
Michael A. CRACKOWER

Serial No.: 10/518,599

Filed: May 31, 2005

For: ACE2 ACTIVATION FOR TREATMENT
OF HEART, LUNG AND KIDNEY
DISEASE AND HYPERTENSION

Group Art Unit: 1652

Examiner: SAIDHA, TEKCHAND

Atty. Dkt. No.: SONN:064US

Confirmation No.: 8087

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

January 26, 2010

Date

Travis M. Wohlers

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the present statement, as evidenced by the date of the enclosed Japanese office action. The Crackower et al. and Donoghue et al. references cited in the Japanese Office Action were previously cited in this case in the references cited by the examiner included with the Office Action dated March 8, 2006 and in the Information Disclosure Statement submitted to the Patent and Trademark Office dated August 11, 2005 respectively, and therefore, copies of these two references are not included with the submission of this Information Disclosure Statement.

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/SONN:064US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis M. Wohlers
Reg. No. 57,423
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 26, 2010